+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 80Years
All Genders
Healthy Volunteers
ID07486102

Phase 1 Study to See How BI 3000202 Is Processed in Adults With and Without Liver Problems

Led by Boehringer Ingelheim · Updated on 2026-05-14

44

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying how the body absorbs and processes a medicine called BI 3000202 in adults aged 18 to 80 years, including both healthy individuals and those with liver problems. The goal is to understand the effects of different levels of liver impairment on the drugs behavior in the body. This is a Phase I, open-label study led by Boehringer Ingelheim focusing on safety and tolerability as well as drug levels in the blood. All participants take a single tablet of BI 3000202. Those with liver problems may continue their usual liver treatments during the study. Participants are grouped based on liver function levels, ranging from normal to severe hepatic impairment. The study lasts about one month, with around 11 visits to the study site, some of which may be done by phone. Certain visits require an overnight stay. During the study, doctors regularly measure the amount of BI 3000202 in the participants blood to assess how the drug is processed. Health checks are performed to monitor safety. The main outcomes include measuring the drug concentration over time and the highest concentration reached in the blood within up to eight days after dosing. Participants will be closely observed throughout their involvement, which lasts about one month in total.

CONDITIONS

Brief Title

A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems

Research Team

B

Boehringer Ingelheim

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here